{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:05:07Z","timestamp":1793329507667,"version":"4.5.0"},"reference-count":4,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,10,1]]},"DOI":"10.1001\/jamacardio.2023.3357","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T15:32:37Z","timestamp":1693236757000},"page":"978","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1001","volume":"8","author":[{"given":"Sharlene M.","family":"Day","sequence":"first","affiliation":[{"name":"University of Pennsylvania, Philadelphia"},{"name":"Associate Editor for Translational Science, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Udelson","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert O.","family":"Bonow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hen230004r1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148557","article-title":"Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure.","volume":"132","author":"Day","year":"2022","journal-title":"J Clin Invest"},{"issue":"10253","key":"hen230004r2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"hen230004r3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"hen230004r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial.","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2809053\/jamacardiology_day_2023_en_230004_1695753735.8787.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T15:12:19Z","timestamp":1697037139000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2809053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":4,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.3357","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}